Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate

Gönczöl, Éva and Berencsi, K. and Pincus, S. and Endrész, Valéria (1995) Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. VACCINE, 13 (12). pp. 1080-1085. ISSN 0264-410X

Text 1184131.pdf Restricted to Registered users only Download (881kB) | Request a copy

Abstract

Successful vaccination against the human cytomegalovirus (HCMV) requires induction. of both neutralizing antibody and cytotoxic T lymphocyte (CTL) responses. The HCMV glycoprotein B (gB, UL55) would be one of the most important immunogens to induce neutralizing antibodies. We tested the immunogenicity of art ALVAC (canarypox)-HCPAV-gB (ALVAC-gB) recombinant in mice and guinea pigs in order to provide preclinical data for a phase I clinical trial of a HCMV vaccine candidate, AL VAC is an attenuated vaccine strain of canarypox virus which replicates productively in avian species but abortively in mammalian cells, The ALVAC-gB recombinant inoculated subcutaneously in mice and intramuscularly in guinea pigs induced HCMV-specific neutralizing antibodies and gB-specific CTL responses. Ultraviolet irradiation of the ALVAC-gB recombinant before immunization diminished CTL responses, indicating that intracellular expression and processing of gB-protein were necessary for CTL induction. Prior immunity to vaccinia virus did Plot decrease immunogenicity of the ALVAC-gB recombinant in mice. Thus, despite its host range restriction, ALVAC-gB is potentially capable of inducing both humoral and cell-mediated immune responses to HCMV in both vaccinia-immune and non-immune individuals.

Actions (login required)

Edit Item